Krishna Vaddi insider trades

Open-market stock purchases and sales by Krishna Vaddi, CEO at Prelude Therapeutics Inc, from SEC Form 4 filings since Sep 29, 2020.

Track record: 33% of 6 scored buys are up 5% or more since purchase, averaging +66%.

Recent trades

DateStockTradeValue
Feb 4, 2026PRLD Prelude Therapeutics IncBought (not open market)—

Companies traded

  • PRLD Prelude Therapeutics Inc: 15 buys, last Feb 4, 2026

Get free alerts when Krishna Vaddi files a new trade →